United States Overactive Bladder Market (Anticholinergics & Beta 3 Adrenoreceptor Agonists): Industry Analysis & Outlook (2020-2030)
Overactive bladder (OAB) syndrome is a chronic medical condition which has a significant impact on the quality of life in a major amount of the population. Overactive bladder is the name given to a group of urinary symptoms that include a strong, uncontrollable urge to urinate at unexpected times, which may result in urine leakage (incontinence), and frequent urination during the day and night. OAB affects performance of daily activities and social functions such as work, traveling, physical exercise, sleep, and sexual function. OAB is a prevalent condition that affects the lives of millions of adults in the US and around the world. An estimated 30 million Americans suffer from overactive bladder, which is uncomfortable, disturbing, and potentially severe.
The treatment approaches for OAB includes behavioral therapy, such as bladder training and pelvic floor exercises. Second line treatment includes pharmacological intervention, historically with anticholinergic medications and more recently with the novel Beta 3 agonist mirabegron. For patients with persistent OAB symptoms, third-line treatment includes procedural therapy using BOTOX injected directly into the bladder to induce temporary muscle paralysis or neuromodulation to enhance neural signals and inhibit reflex detrusor contraction.
The US Overactive Bladder market is set to experience favorable growth driven by factors such rising ageing population, increasing health care expenditure, growing obese population, surging diabetic prevalence and increasing coffee intake. The major trends observed in this market include advancing innovative therapies, increasing awareness for OAB and development of gene therapy. However, the growth of the market is constrained by challenges such as entry of generic drugs in the market, stringent regulations and side effects of oral therapies of OAB.
The report “United States Overactive Bladder Market (Anticholinergics & Beta 3 Adrenoreceptor Agonists): Industry Analysis & Outlook (2020-2030)” analyses the development of the respective market. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Astellas Pharma Inc., Hisamitsu Pharmaceutical Co., Inc., Pfizer Inc. and Allergan Plc. are being profiled along with their key financials and strategies for growth.
The treatment approaches for OAB includes behavioral therapy, such as bladder training and pelvic floor exercises. Second line treatment includes pharmacological intervention, historically with anticholinergic medications and more recently with the novel Beta 3 agonist mirabegron. For patients with persistent OAB symptoms, third-line treatment includes procedural therapy using BOTOX injected directly into the bladder to induce temporary muscle paralysis or neuromodulation to enhance neural signals and inhibit reflex detrusor contraction.
The US Overactive Bladder market is set to experience favorable growth driven by factors such rising ageing population, increasing health care expenditure, growing obese population, surging diabetic prevalence and increasing coffee intake. The major trends observed in this market include advancing innovative therapies, increasing awareness for OAB and development of gene therapy. However, the growth of the market is constrained by challenges such as entry of generic drugs in the market, stringent regulations and side effects of oral therapies of OAB.
The report “United States Overactive Bladder Market (Anticholinergics & Beta 3 Adrenoreceptor Agonists): Industry Analysis & Outlook (2020-2030)” analyses the development of the respective market. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Astellas Pharma Inc., Hisamitsu Pharmaceutical Co., Inc., Pfizer Inc. and Allergan Plc. are being profiled along with their key financials and strategies for growth.
1. MARKET OVERVIEW
1.1 Overactive Bladder
1.2 Symptoms & Diagnosis
1.3 Treatment
1.4 Overactive Bladder with BPH
2. US MARKET ANALYSIS
2.1 Overactive Bladder Market
2.1.1 US Overactive Bladder Market Forecast by Value
2.1.2 US Overactive Bladder Market by Drug Class
2.1.3 US Anticholinergics Market Forecast by Value
2.1.4 US Beta 3 Adrenoreceptor Agonists Market Forecast by Value
2.1.5 US Beta 3 Adrenoreceptor Agonists Market Penetration by Drug
2.1.6 US Vibegron Drug Revenue Forecast
2.1.7 US Vibegron Prescriptions Volume Forecast
2.1.8 US Mirabegron Prescriptions Volume Forecast
2.1.9 US Overactive Bladder Patient Population Forecast
2.1.10 US Overactive Bladder Treated Patient Population Forecast
2.1.11 US Overactive Bladder Prescriptions Volume Forecast
2.2 Overactive Bladder Market with BPH
2.2.1 US Overactive Bladder with BPH Patient Population Forecast
2.2.2 US Beta 3 Adrenoreceptor Agoinst Market by Penetration Rate
2.2.3 US Beta 3 Adrenoreceptor Agoinst Market Penetration by Drug
2.2.4 US Vibegron Drug Revenue Forecast
2.2.5 US Vibegron Prescriptions Volume Forecast
2.2.6 US Mirabegron Prescriptions Volume Forecast
3. MARKET DYNAMICS
3.1 Growth Drivers
3.1.1 Rising Ageing Population
3.1.2 Increasing Health Care Expenditure
3.1.3 Growing Obese Population
3.1.4 Surging Diabetic Prevalence
3.1.5 Increasing Coffee Intake
3.2 Key Trends & Development
3.2.1 Advancing Innovative Therapies
3.2.2 Rising Awareness for OAB
3.2.3 Development of Gene Therapy
3.3 Challenges
3.3.1 Entry of Generic Drugs
3.3.2 Stringent Regulations
3.3.3 Side Effects of Oral Therapies
4. COMPETITION
4.1 Global Market
4.1.1 Revenue Comparison by Company
4.1.2 Market Cap Comparison by Company
5. COMPANY PROFILES
5.1 Astellas Pharma Inc.
5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategies
5.2 Hisamitsu Pharmaceutical Co., Inc.
5.2.1 Business Overview
5.2.2 Financial Overview
5.2.3 Business Strategies
5.3 Pfizer Inc.
5.3.1 Business Overview
5.3.2 Financial Overview
5.3.3 Business Strategies
5.4 Allergan Plc.
5.4.1 Business Overview
5.4.2 Financial Overview
5.4.3 Business Strategies
1.1 Overactive Bladder
1.2 Symptoms & Diagnosis
1.3 Treatment
1.4 Overactive Bladder with BPH
2. US MARKET ANALYSIS
2.1 Overactive Bladder Market
2.1.1 US Overactive Bladder Market Forecast by Value
2.1.2 US Overactive Bladder Market by Drug Class
2.1.3 US Anticholinergics Market Forecast by Value
2.1.4 US Beta 3 Adrenoreceptor Agonists Market Forecast by Value
2.1.5 US Beta 3 Adrenoreceptor Agonists Market Penetration by Drug
2.1.6 US Vibegron Drug Revenue Forecast
2.1.7 US Vibegron Prescriptions Volume Forecast
2.1.8 US Mirabegron Prescriptions Volume Forecast
2.1.9 US Overactive Bladder Patient Population Forecast
2.1.10 US Overactive Bladder Treated Patient Population Forecast
2.1.11 US Overactive Bladder Prescriptions Volume Forecast
2.2 Overactive Bladder Market with BPH
2.2.1 US Overactive Bladder with BPH Patient Population Forecast
2.2.2 US Beta 3 Adrenoreceptor Agoinst Market by Penetration Rate
2.2.3 US Beta 3 Adrenoreceptor Agoinst Market Penetration by Drug
2.2.4 US Vibegron Drug Revenue Forecast
2.2.5 US Vibegron Prescriptions Volume Forecast
2.2.6 US Mirabegron Prescriptions Volume Forecast
3. MARKET DYNAMICS
3.1 Growth Drivers
3.1.1 Rising Ageing Population
3.1.2 Increasing Health Care Expenditure
3.1.3 Growing Obese Population
3.1.4 Surging Diabetic Prevalence
3.1.5 Increasing Coffee Intake
3.2 Key Trends & Development
3.2.1 Advancing Innovative Therapies
3.2.2 Rising Awareness for OAB
3.2.3 Development of Gene Therapy
3.3 Challenges
3.3.1 Entry of Generic Drugs
3.3.2 Stringent Regulations
3.3.3 Side Effects of Oral Therapies
4. COMPETITION
4.1 Global Market
4.1.1 Revenue Comparison by Company
4.1.2 Market Cap Comparison by Company
5. COMPANY PROFILES
5.1 Astellas Pharma Inc.
5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategies
5.2 Hisamitsu Pharmaceutical Co., Inc.
5.2.1 Business Overview
5.2.2 Financial Overview
5.2.3 Business Strategies
5.3 Pfizer Inc.
5.3.1 Business Overview
5.3.2 Financial Overview
5.3.3 Business Strategies
5.4 Allergan Plc.
5.4.1 Business Overview
5.4.2 Financial Overview
5.4.3 Business Strategies
LIST OF CHARTS
Normal Bladder versus Overactive Bladder
OAB Treatment Approaches
US Overactive Bladder Market Forecast by Value (2020-2030)
US Overactive Bladder Market by Drug Class (2020/2030)
US Anticholinergics Market Forecast by Value (2020-2030)
US Beta 3 Adrenoreceptor Agonists Market Forecast by Value (2020-2030)
US Beta 3 Adrenoreceptor Agonists Market Penetration by Drug (2020/2024/2030)
US Vibegron Drug Revenue Forecast (2020-2030)
US Vibegron Prescriptions Volume Forecast (2020-2030)
US Mirabegron Prescriptions Volume Forecast (2020-2030)
US Overactive Bladder Patient Population Forecast (2020-2030)
US Overactive Bladder Treated Patient Population Forecast (2020-2030)
US Overactive Bladder Prescriptions Volume Forecast (2020-2030)
US Overactive Bladder with BPH Patient Population Forecast (2020-2030)
US Beta 3 Adrenoreceptor Agoinst Market by Penetration Rate (2020-2030)
US Beta 3 Adrenoreceptor Agoinst Market Penetration by Drug (2021/2024/2030)
US Vibegron Drug Revenue Forecast (2021-2030)
US Vibegron Prescriptions Volume Forecast (2021-2030)
US Mirabegron Prescriptions Volume Forecast (2021-2030)
US Ageing Population (65 years & Above) (2013-2017)
US Healthcare Expenditure; 1990-2020 (%)
US Obese Population (20 years & Above) (2008-2017)
US Diagnosed Diabetic Population (2010-2017)
Domestic Consumption of Coffee in the US (2014-2018)
Revenue Comparison by Company (2017)
Market Cap Comparison by Company (2017)
Astellas Pharma Sales by Business Segments (2018)
Astellas Pharma Sales and Net Income (2014-2018)
Hisamitsu Pharmaceutical Sales by Business Segments (2018)
Hisamitsu Pharma Net Sales and Net Income (2014-2018)
Hisamitsu Pharmaceutical Research & Development Expenditure (2014-2018)
Pfizer Inc.'s Revenue Share by Major Business Segment (2017)
Pfizer Inc.’s Revenue and Net Income (2013-2017)
Pfizer Inc. R&D Expenses (2015-2017)
Allergan Plc Net Revenues by Business Segments (2017)
Allergan Plc Net Revenues and Net Income (Loss) (2013-2017)
Allergan Plc Research and Development Expenditures (2015-2017)
Normal Bladder versus Overactive Bladder
OAB Treatment Approaches
US Overactive Bladder Market Forecast by Value (2020-2030)
US Overactive Bladder Market by Drug Class (2020/2030)
US Anticholinergics Market Forecast by Value (2020-2030)
US Beta 3 Adrenoreceptor Agonists Market Forecast by Value (2020-2030)
US Beta 3 Adrenoreceptor Agonists Market Penetration by Drug (2020/2024/2030)
US Vibegron Drug Revenue Forecast (2020-2030)
US Vibegron Prescriptions Volume Forecast (2020-2030)
US Mirabegron Prescriptions Volume Forecast (2020-2030)
US Overactive Bladder Patient Population Forecast (2020-2030)
US Overactive Bladder Treated Patient Population Forecast (2020-2030)
US Overactive Bladder Prescriptions Volume Forecast (2020-2030)
US Overactive Bladder with BPH Patient Population Forecast (2020-2030)
US Beta 3 Adrenoreceptor Agoinst Market by Penetration Rate (2020-2030)
US Beta 3 Adrenoreceptor Agoinst Market Penetration by Drug (2021/2024/2030)
US Vibegron Drug Revenue Forecast (2021-2030)
US Vibegron Prescriptions Volume Forecast (2021-2030)
US Mirabegron Prescriptions Volume Forecast (2021-2030)
US Ageing Population (65 years & Above) (2013-2017)
US Healthcare Expenditure; 1990-2020 (%)
US Obese Population (20 years & Above) (2008-2017)
US Diagnosed Diabetic Population (2010-2017)
Domestic Consumption of Coffee in the US (2014-2018)
Revenue Comparison by Company (2017)
Market Cap Comparison by Company (2017)
Astellas Pharma Sales by Business Segments (2018)
Astellas Pharma Sales and Net Income (2014-2018)
Hisamitsu Pharmaceutical Sales by Business Segments (2018)
Hisamitsu Pharma Net Sales and Net Income (2014-2018)
Hisamitsu Pharmaceutical Research & Development Expenditure (2014-2018)
Pfizer Inc.'s Revenue Share by Major Business Segment (2017)
Pfizer Inc.’s Revenue and Net Income (2013-2017)
Pfizer Inc. R&D Expenses (2015-2017)
Allergan Plc Net Revenues by Business Segments (2017)
Allergan Plc Net Revenues and Net Income (Loss) (2013-2017)
Allergan Plc Research and Development Expenditures (2015-2017)
LIST OF TABLES
Astellas Pharma Major Product Approvals & Launches (2018)
Hisamitsu Pharmaceutical Product Approvals (2018)
Major Business Segments of the Pfizer Inc. (2017)
Pfizer Major Agreements (2018)
Astellas Pharma Major Product Approvals & Launches (2018)
Hisamitsu Pharmaceutical Product Approvals (2018)
Major Business Segments of the Pfizer Inc. (2017)
Pfizer Major Agreements (2018)
